Introduction
============

Epidemiological and laboratory-based studies have identified that infection of high-risk human papillomavirus (HPV) as a necessary but not sufficient cause of cervical cancer (Munoz, [@B12]). More than 100 HPV genotypes have been fully characterized on the basis of the isolation of complete genomes present (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, [@B6]). With the general improvement in HPV DNA testing method, overall HPV prevalence in cervical cancer increased significantly from 85.9% in studies published from 1990 to 1999 to 92.9% in studies published from 2006 to 2009, and the increases were large for the prevalence of multiple HPV infections (from 4.0 to 14.4%; Li et al., [@B8]). Therefore, more and more evidences showed that the occurrence of multiple infections is frequent as opposed to occasional.

Due to the geographic variation of overall HPV prevalence, occurrence also varied worldwide with a range of 0.4% in Spain to 8.3% in Nigeria for multiple infections in cytologically normal women (Clifford et al., [@B1]) and 4% in North America to 19% in Africa in cervical cancer cases, respectively (de et al., [@B3]). However, the reports focusing on the prevalence of multiple infections of HPV among Chinese women and its risk factors were rare. Moreover, the association between multiple HPV infections and cervical lesions remain unclear.

Therefore, we re-analyzed the data from three population-based cross-sectional HPV prevalence surveys among Chinese women performed in 2004--2005 to evaluate the prevalence and its risk factors of multiple HPV infections, and explore the link between the concurrent infection with multiple HPV types and the cervical abnormalities in the certain population in the present study.

Materials and Methods
=====================

Study subjects
--------------

Between 2004 and 2005, the Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CIHCAMS) and International Agency for Research on Cancer (IARC) collaborated and performed three population-based HPV prevalence surveys among women in rural and urban areas of China, namely Yangcheng County, Shanxi Province (Dai et al., [@B2]), Shenzhen City, Guangdong Province (Wu et al., [@B17]), and Shenyang City, Liaoning Province (Li et al., [@B7]), respectively. Of these three study centers, Yangcheng County is a rural area of China, and the other two centers are urban areas of China.

Details of the surveys have been reported previously. Briefly, women aged 15--59 years without pregnancies and hysterectomies were enumerated. All participants signed an informed consent form recommended by IARC and CIHCAMS ethical review committees, which approved these three studies.

Study procedures
----------------

Study procedures were identical for these three study centers (Li et al., [@B9]). To summarize, a standardized questionnaire interview was administered to all participants by trained interviewers in separated rooms to increase the compliance. Then the participants provided a sample of exfoliated cervical cell for liquid-based cytology (LBC) and HPV testing and then underwent a clinical examination including testing of visual inspection with acetic acid (VIA), visual inspection with Lugol's Iodine solution (VILI), and digital colposcopy.

Laboratory test
---------------

Liquid-based cytology was performed at CIHCAMS, Beijing, China and the results were classified according to the Bethesda System (Solomon et al., [@B14]). All abnormal smears, as well as 10% of normal smears chosen at random were reviewed by a second experienced cytologist. HPV detection was performed in the Department of Pathology at the Vrije University Medical Center, Amsterdam, the Netherlands, using a GP5+/6+ PCR-based enzyme immunoassay. Genotyping of 44 HPV types \[HPV6, 11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 64, 66, 67, 68, 69, 70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to CP8304), 82 (IS39 and MM4 subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8), cand85, 86, cand89 (equivalent to CP6108), and JC9710\] was performed by reverse line blot hybridization of PCR products (van den Brule et al., [@B16]), and HPV types were classified, for some analyses, into high- and low-risk types (Munoz et al., [@B13]).

Biopsies taken and cervical lesions assessment
----------------------------------------------

Cervical biopsies were prepared and read by a pathologist at CIHCAMS, Beijing, China and the histological diagnosis were made by two pathologists. Women with suspected abnormalities found through VIA, VILI, or colposcopy had a colposcopy-directed biopsy-taken and women whose entire squamocolumnar junction could not be visualized underwent endocervical curettage (ECC). In total, 515 women were take biopsies directly. Meanwhile, 54 women were underwent ECC with 28 cases of CIN1 or worse histologically diagnosed.

When LBC results became available, all women with cytologically abnormal lesions (atypical squamous cells of undetermined significance, ASCUS or worse) not detected by VIA, VILI, or digital colposcopy were recalled and had biopsies taken (Li et al., [@B9]). Finally, 64.08% (91/142) women who should be called back visited doctors again for biopsy-taken and 62 cases of CIN1 or worse were histologically diagnosed.

Hence, in this study, cervical abnormalities were defined as low-grade lesions (including the presence of histologically confirmed cervical intraepithelial neoplasia 1 and cytologically confirmed low-grade lesion if histological results absent) or high-grade lesions (including the presence of histologically confirmed cervical intraepithelial neoplasia 2 or worse and the cytologically confirmed high-grade lesion or worse if histological results absent). On account of the performance of multiple screening tests and the high proportion of histological confirmation, women with negative diagnoses of all screening tests were considered as true negative subjects. After combining the histological and cytological diagnosis results together, 109 (4.59%) and 66 (2.78%) cases of low- and high-grade lesions were diagnosed, respectively.

Statistical analysis
--------------------

The prevalence of multiple HPV infections and its corresponding 95% confidence interval (CI) were calculated. Pearson chi-square test was used to evaluate the difference between multiple HPV prevalence across studies. The statistical significance of trends for multiple HPV prevalence among different cervical lesions was assessed by a non-parametric test, which was an extension of the Wilcoxon rank-sum test. Odds ratios (ORs) and its corresponding 95% CI were used to evaluate the risk of cervical lesions with multiple HPV infections and its risk factors (including social-demographic characteristics, reproductive and menstrual factors, sexual behaviors, etc.) by means of an unconditional logistic regression model. A heterogeneity test was used to examine the between-groups difference based on the χ^2^-based *Q* test and the heterogeneity was considered significant if *P* \< 0.05. All analyses were performed using the Stata statistical software (version 11.0, StataCorp, College Station, TX, USA).

Results
=======

A total of 3504 women (941 from Yangcheng County, 1563 from Shenzhen City, and 1000 from Shenyang City) participated in the HPV prevalence surveys, among which 2374 women (662 from Yangcheng County, 1027 from Shenzhen City, and 685 from Shenyang City) underwent gynecological examinations with valid cytology and their HPV results were included in the analysis.

The mean age of the 2374 women was 38.50 ± 10.38 years, varying between 35.19 ± 9.09 years in Shenzhen City and 41.16 ± 10.43 years in Shenyang City. The overall prevalence of HPV infection ranged from 14.80% (95% CI = 12.18--17.74%) in Yangcheng County to 16.79% (95% CI = 14.06--19.80%) in Shenyang City (Figure [1](#F1){ref-type="fig"}). One hundred and eleven women with multiple HPV infections were found among all the participants. The prevalence of multiple HPV infections was 4.68% (95% CI = 3.86--5.60%) with the highest prevalence in Shenyang City (5.26%, 95% CI = 3.71--7.21%), followed by Yangcheng County (4.54%, 95% CI = 3.08--6.41%), and Shenzhen City (4.38%, 95% CI = 3.21--5.82%), respectively (Figure [1](#F1){ref-type="fig"}). There was no significant difference in HPV prevalence among these three centers either for HPV infection of any type (χ^2^ = 1.22, *P* = 0.544) or multiple types (χ^2^ = 0.74, *P* = 0.689). Therefore, we merged the data from these three centers for the further analyses.

![**Prevalence of HPV infections among 2374 women, by study center**.](fonc-01-00038-g001){#F1}

One hundred and eleven women with multiple HPV infections attributed to 28.98% of all of the 383 HPV-positive women, among which 100 (90.09%) were infected with at least one high-risk type. Most common patterns of multiple infections were concurrent infections with two types, which accounted for 74.77% (83/111) of all subjects with multiple HPV infections. With the increase of age, there was no significant increase of number of multiple HPV infections (*P* for trend = 0.524, data not shown). However, though there was also no significant trend in the increase of number of multiple HPV infections with the deterioration of cervical lesions (*P* for trend = 0.927, data not shown), the prevalence of multiple HPV infections increased with the severity of cervical lesions (χ^2^ = 360.06, *P* \< 0.001; Table [1](#T1){ref-type="table"}).

###### 

**Occurrence of multiple infections of HPV by age-group, study area, and cervical lesion**.

  Characteristics         2 Types no. (proportion, %)   ≥3 Types no. (proportion, %)   Total        
  ----------------------- ----------------------------- ------------------------------ ------------ ---------
  Total (*n* = 2374)      83 (74.78)                    28 (25.22)                     111 (4.68)   --
  **Age-group (years)**                                                                             0.270
  15--24 (*n* = 197)      9 (81.82)                     2 (18.18)                      11 (5.58)    
  25--34 (*n* = 769)      24 (75.00)                    8 (25.00)                      32 (4.16)    
  35--44 (*n* = 686)      18 (72.00)                    7 (28.00)                      25 (3.64)    
  45--54 (*n* = 514)      24 (80.00)                    6 (20.00)                      30 (5.84)    
  55--59 (*n* = 208)      8 (61.54)                     5 (38.46)                      13 (6.25)    
  **Study area**                                                                                    0.836
  Rural (*n* = 662)       24 (80.00)                    6 (20.00)                      30 (4.53)    
  Urban (*n* = 1712)      59 (72.84)                    22 (27.16)                     81 (4.73)    
  **Cervical lesions**                                                                              \<0.001
  Normal (*n* = 2199)     53 (75.71)                    17 (24.29)                     70 (3.18)    
  Low-grade (*n* = 109)   11 (68.75)                    5 (31.25)                      16 (14.68)   
  High-grade (*n* = 66)   19 (76.00)                    6 (24.00)                      25 (37.88)   

To further interpret the link between multiple HPV infections and cervical lesions, we did a comparison of the association strength between the risk of cervical lesions and single and multiple infections. The rate of single and multiple infections by cervical lesions were calculated by the formula of single or multiple HPV-positive number divided by the HPV negative number in case of the confoundings between single and multiple HPV infections (Table [2](#T2){ref-type="table"}). It was certain that with the increase of severity of cervical lesions, the prevalence of any HPV type increased. Compared to women with normal cervixes, women with low-grade cervical lesions, as well as women with high-grade lesions, had a significantly higher prevalence of both single (OR = 9.65, 95% CI = 6.26--14.87 and OR = 26.90, 95% CI = 13.27--54.51 for low- and high-grade lesions, respectively) and multiple infections (OR = 9.40, 95% CI = 5.08--17.39 and OR = 62.76, 95% CI = 29.70--132.62 for low- and high-grade lesions, respectively). More interestingly, we also found that the OR values in the subgroups of high-grade lesions were significantly higher than that in the subgroups of low-grade lesions for multiple HPV infections (*P*~heterogeneity~ = 0.044), but not significantly for single HPV infection (*P*~heterogeneity~ = 0.108; Table [2](#T2){ref-type="table"}).

###### 

**Prevalence of single and multiple infections of HPV in cervical lesions**.

  Lesion grade   Any-type infection   Single infection       Multiple infection                                                                                             
  -------------- -------------------- ---------------------- -------------------- ----------------- ---------------------- ------- ---------------- ----------------------- -------
  Normal         12.1 (266/1933)      Ref.^f^                                     9.21 (196/1933)   Ref.                           3.49 (70/1933)   Ref.                    
  Low-grade      56.88 (62/47)        9.59 (6.42--14.30)                          49.46 (46/47)     9.65 (6.26--14.87)             25.40 (16/47)    9.40 (5.08--17.39)      
  High-grade     83.33 (55/11)        36.33 (18.78--70.29)   0.044                73.17 (30/11)     26.90 (13.27--54.51)   0.108   69.44 (25/11)    62.76 (29.70--132.62)   0.044

*^a^OR, odds ratio; ^b^95% CI, 95% confidence interval; ^c^*P* values of heterogeneity test for ORs between-groups; ^d^*n*+, number of HPV positivity; ^e^number of HPV negativity; ^f^Ref., reference group*.

To explore the implications of individual HPV types in multiple infections, we analyzed the prevalence of single and multiple infections with the individual HPV types in cervical lesions. Generally, HPV16 was by far the most common type with a multiple prevalence of 1.39% (95% CI = 0.96--1.95%), followed by HPV58 (1.10%, 95% CI = 0.72--1.60%) and HPV52 (0.84%, 95% CI = 0.52--1.30%), respectively (Table [3](#T3){ref-type="table"}). After being stratified by cervical lesions, we found that the prevalence ratio (PR) between multiple and single infection was less than 1.00 for three HPV types among women with cervical lesions (low-grade lesion or worse), and, in the increasing order, were 0.52 for HPV16 and 0.90 for both HPV31 and HPV33. All the remaining HPV types were more frequently found as a part of a multiple infection than a single infection in the subgroup of cervical lesions presence with the PR over than 1.00. As the representative of low-risk HPV types, HPV6 and 11 were absent from single infection among women with cervical lesions (Table [3](#T3){ref-type="table"}).

###### 

**Prevalence of single and multiple infections of individual HPV types among Chinese women with or without cervical lesions**.

  HPV type              Total (*n* = 2374)   Normal cervix (*n* = 2199)   Cervix with low-grade lesions or worse (*n* = 175)                                                                                              
  --------------------- -------------------- ---------------------------- ---------------------------------------------------- ------------------- ------------------- ------ --------------------- --------------------- -------
  **ALPHA-9 SPECIES**                                                                                                                                                                                                     
  HPV16 (*n* = 87)      2.27 (1.71--2.96)    1.39 (0.96--1.95)            0.61                                                 1.32 (0.88--1.90)   1.15 (0.73--1.72)   0.87   19.4 (13.08--27.12)   10.1 (4.95--17.79)    0.52
  HPV31 (*n* = 25)      0.59 (0.32--0.99)    0.46 (0.23--0.83)            0.79                                                 0.52 (0.26--0.92)   0.45 (0.21--0.85)   0.87   2.24 (0.46--6.4)      2.02 (0.25--7.11)     0.90
  HPV33 (*n* = 17)      0.34 (0.15--0.66)    0.38 (0.17--0.72)            1.13                                                 0.23 (0.08--0.55)   0.35 (0.14--0.72)   1.52   2.24 (0.46--6.4)      2.02 (0.25--7.11)     0.90
  HPV35 (*n* = 6)       0.13 (0.03--0.37)    0.13 (0.03--0.37)            1.00                                                 0.09 (0.01--0.34)   0.10 (0.01--0.36)   1.11   0.75 (0.02--4.09)     1.01 (0.03--5.5)      1.35
  HPV52 (*n* = 46)      1.10 (0.72--1.60)    0.84 (0.52--1.30)            0.77                                                 0.89 (0.54--1.39)   0.65 (0.35--1.11)   0.73   5.22 (2.13--10.47)    7.07 (2.89--14.03)    1.35
  HPV58 (*n* = 50)      1.01 (0.65--1.50)    1.10 (0.72--1.60)            1.08                                                 0.66 (0.36--1.1)    0.75 (0.42--1.23)   1.14   7.46 (3.64--13.3)     11.11 (5.68--19.01)   1.49
  HVP67 (*n* = 8)       0.08 (0.01--0.30)    0.25 (0.09--0.55)            3.00                                                 0.09 (0.01--0.34)   0.20 (0.05--0.51)   2.22   0.00 (0.00--2.72)     2.02 (0.25--7.11)     NA^c^
  **ALPHA-7 SPECIES**                                                                                                                                                                                                     
  HPV18 (*n* = 26)      0.55 (0.45--1.20)    0.55 (0.45--1.20)            1.00                                                 0.42 (0.19--0.8)    0.30 (0.11--0.65)   0.71   2.99 (0.82--7.47)     7.07 (2.89--14.03)    2.36
  HPV45 (*n* = 15)      0.17 (0.05--0.43)    0.46 (0.23--0.83)            2.75                                                 0.09 (0.01--0.34)   0.35 (0.14--0.72)   3.89   1.49 (0.18--5.29)     4.04 (1.11--10.02)    2.71
  HPV39 (*n* = 25)      0.46 (0.23--0.83)    0.59 (0.32--0.99)            1.27                                                 0.42 (0.19--0.8)    0.45 (0.21--0.85)   1.07   1.49 (0.18--5.29)     5.05 (1.66--11.39)    3.39
  HVP59 (*n* = 15)      0.38 (0.17--0.72)    0.25 (0.09--0.05)            0.67                                                 0.33 (0.13--0.68)   0.10 (0.01--0.36)   0.30   1.49 (0.18--5.29)     4.04 (1.11--10.02)    2.71
  HVP68 (*n* = 8)       0.21 (0.07--0.49)    0.13 (0.03--0.37)            0.60                                                 0.19 (0.05--0.48)   0.05 (0.00--0.28)   0.26   0.75 (0.02--4.09)     2.02 (0.25--7.11)     2.69
  **OTHER SPECIES**                                                                                                                                                                                                       
  HPV6 (*n* = 5)        0.17 (0.05--0.43)    0.04 (0.00--0.23)            0.25                                                 0.19 (0.05--0.48)   0.05 (0.00--0.28)   0.26   0.00 (0.00--2.72)     0.00 (0.00--3.66)     NA
  HPV11 (*n* = 9)       0.17 (0.05--0.43)    0.21 (0.07--0.49)            1.25                                                 0.19 (0.05--0.48)   0.15 (0.03--0.44)   0.79   0.00 (0.00--2.72)     2.02 (0.25--7.11)     NA

*^a^95% CI, 95% confidence interval; ^b^prevalence ratio, prevalence of multiple infections/prevalence of single infection; ^c^NA, not available*.

For the analysis of risk factors of multiple HPV infection, we found that women older than 45 years (OR = 1.49, 95% CI = 1.01--2.22) and have had more than three sexual partners (OR = 2.11, 95% CI = 1.06--4.19) were associated with multiple HPV infections using a binary logistic regression. Results from multivariable models also confirmed that women older than 45 years (adjusted OR = 1.52, 95% CI = 1.02--2.27) and have had more than three sexual partners (adjusted OR = 2.10, 95% CI = 1.05--4.17) were significantly associated with multiple HPV infections after adjustment for age-groups (\<45 and ≥45 years), study areas (rural and urban), and number of sexual partners (1, 2, and ≥3 sexual partners; Table [4](#T4){ref-type="table"}). In addition, we also revealed that with the increase of number of sexual partners, the prevalence of multiple HPV infections significantly increased (*P* for trend = 0.047; data not shown).

###### 

**Characteristics related to multiple HPV infections among 2374 Chinese women**.

  Characteristics                           Multiple infections no. (%)   Negative no. (%)   OR^a^ (95% CI)^b^   Adjusted^c^ OR (95% CI)
  ----------------------------------------- ----------------------------- ------------------ ------------------- -------------------------
  **Age-group (years)**                                                                                          
  \<45                                      68 (4.64)                     1399 (95.36)       Ref.                Ref.
  ≥45                                       43 (6.77)                     592 (93.23)        1.49 (1.01--2.22)   1.52 (1.02--2.27)
  **Area**                                                                                                       
  Rural                                     30 (5.05)                     564 (94.95)        Ref.                Ref.
  Urban                                     81 (5.37)                     1427 (94.63)       1.07 (0.69--1.64)   1.14 (0.74--1.76)
  **Education**                                                                                                  
  ≤Junior high school                       51 (4.88)                     994 (95.12)        Ref.                Ref.
  ≥Senior high school                       60 (5.68)                     997 (94.32)        1.17 (0.80--1.72)   1.43 (0.90--2.89)
  **Marriage times**                                                                                             
  1                                         105 (5.23)                    1904 (94.77)       Ref.                Ref.
  ≥2                                        6 (6.45)                      87 (93.55)         1.25 (0.53--2.93)   1.20 (0.51--2.83)
  **Age at menarche (years)**                                                                                    
  ≤13                                       22 (3.61)                     587 (96.39)        Ref.                Ref.
  ≥14                                       89 (5.96)                     1404 (94.04)       1.69 (1.05--2.72)   1.60 (0.98--2.61)
  **Voluntary abortion times**                                                                                   
  1                                         33 (4.73)                     664 (95.27)        Ref.                Ref.
  2                                         16 (4.53)                     337 (95.47)        0.95 (0.52--1.76)   0.91 (0.49--1.68)
  ≥3                                        8 (4.71)                      162 (95.29)        0.99 (0.45--2.19)   0.92 (0.42--2.05)
  **Spontaneous abortions times**                                                                                
  1                                         5 (3.27)                      148 (96.73)        Ref.                Ref.
  ≥2                                        1 (3.33)                      29 (96.67)         1.02 (0.11--9.06)   0.96 (0.10--8.82)
  **Live birth number**                                                                                          
  0                                         6 (5.04)                      113 (94.96)        Ref.                Ref.
  1                                         66 (5.27)                     1187 (94.73)       1.05 (0.44--2.47)   0.91 (0.38--2.17)
  2                                         20 (4.61)                     414 (95.39)        0.91 (0.36--2.32)   0.62 (0.22--1.76)
  ≥3                                        10 (5.99)                     157 (94.01)        1.20 (0.42--3.40)   0.66 (0.19--2.25)
  **Age at first delivery (years)**                                                                              
  ≤24                                       49 (5.07)                     917 (94.93)        Ref.                Ref.
  ≥25                                       47 (5.32)                     837 (94.68)        1.05 (0.70--1.59)   1.02 (0.62--1.67)
  **Condom use**                                                                                                 
  No                                        59 (5.06)                     1108 (94.94)       Ref.                Ref.
  Yes                                       22 (2.44)                     879 (97.56)        1.11 (0.76--1.63)   1.25 (0.78--1.99)
  **Number of sexual partners**                                                                                  
  1                                         88 (4.96)                     1686 (95.04)       Ref.                Ref.
  2                                         13 (5.73)                     214 (94.27)        1.16 (0.64--2.12)   1.22 (0.67--2.22)
  ≥3                                        10 (9.90)                     91 (90.10)         2.11 (1.06--4.19)   2.10 (1.05--4.17)
  **Age at first intercourse (years)**                                                                           
  \<20                                      20 (4.95)                     384 (95.05)        Ref.                Ref.
  ≥20                                       91 (5.36)                     1607 (94.64)       1.09 (0.66--1.79)   1.11 (0.63--1.98)
  **Husbands' extra-marital intercourse**                                                                        
  No                                        90 (5.18)                     1646 (94.82)       Ref.                Ref.
  Yes                                       16 (5.95)                     253 (94.05)        1.16 (0.67--2.00)   1.18 (0.68--2.05)

*^a^OR, odds ratio; ^b^95% CI, 95% confidence interval; ^c^adjusted for age-groups, study areas, and number of sexual partners*.

Discussion
==========

Since HPV prevalence varies across the geographic regions, it is reasonable to postulate that the prevalence of multiple HPV infections is also heterogenic in different geographic regions. Based on a series of population-based HPV prevalence surveys performed by IARC all over the world with a standardized protocol, it is easy and reliable for us to compare the multiple HPV infections among different geographic areas. In this population-based multi-center cross-sectional study, we found that the prevalence of multiple HPV infections among cytologically normal women in China (3.18, 95% CI = 2.49--4.00%) was higher than that in the other countries in Asia and Europe but lower than that in South America and Sub-Saharan Africa (Clifford et al., [@B1]). But the proportion (28.98% in our study) of the multiple HPV infections among all HPV-positive Chinese women was similar to other report (Mendez et al., [@B11]). The results revealed that the co-infection with at least two types were frequent among Chinese women other than occasional. We also found that there was no association between number of HPV types and the presence of cervical abnormalities, which was consistent with the results of a cohort study performed in rural Costa Rica (Herrero et al., [@B5]). The results suggested that the risk of cervical lesions may be more associated with the combination of HPV subtypes as opposed to the number of types. We also found that the prevalence of single HPV infection was higher than that of multiple HPV infections in women with cervical lesions for HPV16, 31, and 33. In addition, the single infection with low-risk HPV types was absent and the prevalence of multiple infections with low-risk HPV types was also very low in the women with cervical abnormalities, which may suggest a stronger carcinogenesis for Alpha-9 Species of HPV among the certain population, especially for HPV16, 31, and 33.

Age and sexual behavior were shown as the major risk factors of multiple HPV infections among the certain population. In contrast to studies in some other areas, such as Denmark (Mejlhede et al., [@B10]), older age was considered as a risk factor to multiple infections in Chinese women. We should note that, differing from the other areas with the peak of HPV prevalence in younger women, China showed a flat age-specific prevalence curve of any HPV type (Franceschi et al., [@B4]). It implied a great possibility of the low rate of the clearance of HPV infection in Chinese women compared to women in Europe and North America. Therefore, due to the decrease of the immunity, the increase of multiple HPV infection in older women was understandable. As we have known, the most common mode of transmission of anogenital HPV is by sexual activity. Many studies proved the association between sexual behaviors and HPV prevalence. However, the relationship between sexual behaviors and multiple HPV infections remains unclear. Our study showed that multiple sexual partners was another risk factor of multiple HPV infection, and with the increase of number of sexual partners, the prevalence of multiple HPV infection increased (*P* for trend = 0.047). Considering the low exposure to multiple sexual partners (5.67%, 95% CI = 4.00--7.76% for ≥3 sexual partners) and the higher rate of multiple HPV infection (6.77%, 95% CI = 4.94--9.01%) among the older Chinese women, we may postulate that the occurrence of multiple HPV infections among Chinese women is probably mainly due to the accumulation of infections other than co-occurrence at one time. Hence, the great probability of persistent infection among Chinese women can explain the high incidence of cervical cancer in China to an extent.

More interestingly, we observed that though multiple HPV infection increased the risk of both low- and high-grade cervical lesions, the risk of high-grade lesions was increased more significantly than low-grade lesions (*P*~heterogeneity~ = 0.044). But the pattern did not show for single HPV infection (*P*~heterogeneity~ = 0.108). The results implied that multiple HPV infections could be used as a substantial indicator to identify the high-risk population in Chinese women either for public prevention or clinical implication (Spinillo et al., [@B15]).

The main limitation of the study is the relatively small sample size, especially in stratified analyses. On the other hand, the cross-sectional study design was less efficient in demonstrating the mechanism and natural history of multiple HPV infections among Chinese women clearly. The multi-center large scale cohort studies on the natural history of HPV infection will be very helpful in the near future. However, as we know, it's the first time the profile of multiple HPV infections among Chinese women was provided. The use of a standardized protocol and methodology in these three study centers made the comparison and data combination reasonable and believable. From a practical viewpoint, the studies described the prevalence of multiple HPV infection among women with or without cervical lesions, and its risk factors. The findings of our study provide the basic and scientific data for the introduction of vaccinations in China in the future.
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